SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle (ORCL) is trending after reporting strong earnings that beat estimates and raising its FY27 revenue guidance, driven by explosive cloud infrastructure growth and a massive increase in Remaining Performance Obligations from AI contracts. The community is actively discussing whether these robust results, which highlight significant customer prepayments for AI capacity, will finally overcome prior concerns about the company's capital expenditures.

AeroVironment, Inc. engages in the design, development, and production of multi-domain robotic systems and related services for government agencies and businesses. It operates through the following business segments: UnCrewed Systems, Loitering Munitions Systems, and MacCready Work. The UnCrewed Systems segment focuses primarily on small UAS products designed to operate reliably at lower altitudes in a wide range of environmental conditions. The Loitering Munitions Systems segment focuses primarily on tube-launched aircraft that deploy with the push of a button, fly at higher speeds than small UAS products, and perform either effects delivery or reconnaissance missions, and related support services including training, spare parts, product repair, and product replacement. The MacCready Works segment focuses on customer-funded research and development in the areas of HAPS, robotics, sensors, software analytics, data intelligence, and connectivity. The company was founded by Paul B. MacCready, Jr. in July 1971 and is headquartered in Arlington, VA.

AeroVironment Inc.

AeroVironment (AVAV) is trending after a Q3 earnings miss and news of a Space Force contract termination caused a sharp sell-off, with a new Army contract and record backlog leading many to debate if the market has overreacted amidst strong demand for drone technology.

Groupon, Inc. engages in the global scaled two-sided marketplace that connects consumers to merchants. It operates through the North America and International geographical segments. The company was founded by Andrew D. Mason, Eric Paul Lefkofsky, and Bradley A. Keywell in October 2008 and is headquartered in Chicago, IL.

Groupon Inc

Groupon is trending after reporting surprisingly strong recent results, which defied expectations by showing a return to profitability and revenue growth. This has sparked a heated debate among investors, with bulls hailing a fundamental turnaround and potential short squeeze, while skeptics view the surge as unsustainable manipulation given the company's historical challenges and perceived declining relevance.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. It offers Alpha, Beta, Gamma, and orbital transfer vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 27, 2017 and is headquartered in Cedar Park, TX.

Firefly Aerospace Inc.

Firefly Aerospace (FLY) is trending amid intense community discussion surrounding its upcoming rocket launch, where anticipation for success clashes with frustration over repeated delays, while investors also consider its long-term potential in the burgeoning space and defense sector, including "Golden Dome" contracts.

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after reporting its first-ever quarterly profit and providing strong delivery guidance, leading to multiple analyst upgrades and fueling community excitement about a potential short squeeze and a long-awaited rebound for the EV innovator, especially with its advanced in-house chip development.

The Beachbody Co., Inc. operates as a health and wellness company. It offers holistic health and wellness platforms. The company's product offerings include digital subscriptions, nutritional products, and connected fitness products. Digital subscriptions include Beachbody On Demand (BOD) and Openfit. The subscriptions are renewed on a monthly, quarterly, or annual basis and include unlimited access to a library of live and on-demand fitness and nutrition content. Nutritional products include Shakeology, Beachbody Performance supplements, BEACHBARs, and others. Connected fitness products include The Beachbody Bike (also known as Myx), which is equipped with a swivel touch screen that enables users to engage with content beyond the indoor cycling experience and encourages broader cross-training, incorporating resistance training and yoga for a more holistic fitness experience and healthier results. The company was founded by Carl Daikeler and Jon Congdon in 1998 and is headquartered in El Segundo, CA.

Beachbody Company Inc (The) - Ordinary Shares - Class A

The Beachbody Company is surging after reporting its first full-year operating income since going public and significant improvements in net income for Q4 2025, signaling a potential turnaround. While some investors remain skeptical given past performance, the community is actively discussing the substantial earnings beat, positive adjusted EBITDA, and strategic shifts as catalysts for further upside.

Oxford Lane Capital Corp. is a closed-end management investment company, which engages in investing in debt and equity tranches of collateralized loan obligation vehicles. The company was founded on June 9, 2010 and is headquartered in Greenwich, CT.

Oxford Lane Capital Corp

Oxford Lane Capital is trending after a substantial decline in its Net Asset Value and a 50% reduction in its dividend, sparking intense community discussion about the stock's future and management's strategy amid wider concerns surrounding the CLO sector.

Franco-Nevada Corp. engages in the management of gold-focused royalties and streams portfolio. It provides investors with gold price and exploration optionality while limiting exposure to many of the risks of operating companies. The company was founded in 1983 and is headquartered in Toronto, Canada.

Franco-Nevada Corporation

FNV is attracting buzz after its strong Q4 earnings beat, increased dividend, and optimistic 2026 guidance that notably excludes a Cobre Panama restart, leading the community to view any potential return of the mine as pure upside in the current booming gold market.

SuRo Capital Corp. operates as a publicly traded investment fund. It seeks to invest in a broad range of sectors and industries as well as to provide investors with access to such companies through its publicly traded common stock. The company was founded by Mark David Klein on September 17, 2010 and is headquartered in New York, NY.

SuRo Capital Corp

SuRo Capital Corp.

SuRo Capital is trending as recent valuation upgrades for its significant portfolio holdings like OpenAI and CoreWeave are fueling community discussions around a substantial increase in Net Asset Value. Investors are actively anticipating future dividends and viewing the current stock price as notably undervalued given these developments in the burgeoning AI infrastructure sector.

goeasy Ltd. engages in the provision of non-prime leasing and lending services. The company was founded by Gordon J. Reykdal on December 14, 1990 and is headquartered in Mississauga, Canada.

Goeasy Ltd

Goeasy Ltd. is trending due to the unexpected suspension of its dividend and withdrawal of financial guidance, alongside reports of significant loan write-offs. This has fueled community speculation about potential mismanagement, class-action lawsuits, and a broader credit crisis, despite some investors viewing the sharp decline as an oversold opportunity.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

What's Going On With CRISPR Therapeutics Stock Today?

CRISPR Therapeutics fell Tuesday after unveiling a $350 million convertible notes offering, overshadowing recent momentum from Casgevy uptake and fourth-quarter revenue growth.read more...

CRISPR Therapeutics (NASDAQ:CRSP) Shares Gap Down - What's Next?

CRISPR Therapeutics (NASDAQ:CRSP) Shares Gap Down - What's Next...

<ul class="summary-bullets"><li>CRISPR Therapeutics said the debt securities will rank as senior unsecured obligations.</li><li>Interest payments will be made twice each year, with the first scheduled payment expected in September 2026.</li><li>In January, the company said it had around $2 billion in cash, cash equivalents, and marketable securities.</li></ul>CRISPR Therapeutics AG (CRSP) on Tuesday announced plans to raise capital through a private debt offering as the gene-editing biotechnology company continues funding research and development efforts.&nbsp;The company said it intends to issue $350 million in convertible senior notes, scheduled to mature in 2031, subject to prevailing market conditions and investor demand.<h2 class="st-heading-2">Structure Of The Convertible Notes</h2>According to the company, the debt securities will rank as senior unsecured obligations.&nbsp;Interest payments will be made twice each year, with the first scheduled payment expected in September 2026.&nbsp;Unless the notes are converted into shares, repurchased, or redeemed earlier, they will come due on Mar. 1, 2031. If investors choose to convert the notes, CRISPR will settle the conversion by issuing common shares with a nominal value of CHF 0.03 ($0.039) each.CRISPR Therapeutics said it expects to allocate the net proceeds from the sale for broad corporate needs.&nbsp;<a href="https://stocktwits.com/symbol/CRSP">CRISPR Therapeutics stock</a> traded over 6% lower in Tuesday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock changed to ‘bullish’ from ‘bearish’ territory the previous day. Message volume flipped to ‘high’ from ‘low’ levels in 24 hours.&nbsp;<h2 class="st-heading-2">2026 Goals</h2>CRISPR Therapeutics is developing a wide range of programs in blood disorders, cancer, regenerative medicine, heart and autoimmune diseases, and other rare conditions. CASGEVY is the first CRISPR-based therapy for patients with sickle cell disease and transfusion-dependent beta thalassemia.In January, it&nbsp;outlined its strategic priorities for 2026, highlighting multiple expected milestones across its gene-editing and siRNA portfolios. It also emphasized a strong financial position, with around $2 billion in cash, cash equivalents, and marketable securities to support ongoing research and commercial activities.CRSP stock has gained over 23% in the last 12 months.&nbsp;Exchange Rate: 1CHF=1.29USDAlso See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/capr-stock-surged-today-what-is-fueling-the-rally/cZdovHXRI7O">CAPR Stock Surged 17% Today — What’s Fueling The Rally?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Crispr Therapeutics logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Why Is CRSP Stock Falling Pre-Market Today?

CRISPR Therapeutics AG (CRSP) on Tuesday announced plans to raise capital through a private debt offering as the gene-editing biotechnology company continues funding research and development efforts. 

Why Is CRSP (CRISPR Therapeutics) Stock Falling Pre-Market Today?

Equity

The company plans to issue $350 million in convertible senior notes that are scheduled to mature in 2031.


<ul class="summary-bullets"><li>TD Cowen raised its price target on Rivian shares to $20 from $17.</li><li>The firm estimates that annual sales for R2 could eventually range from roughly 212,000 to 335,000 vehicles.</li><li>Rivian plans to price the R2 SUV at roughly $45,000 with roll-out beginning in the second-quarter.&nbsp;</li></ul>Rivian Automotive Inc. (RIVN) received a vote of confidence from TD Cowen, which upgraded the electric vehicle maker’s stock to a ‘Buy’ rating from ‘Hold’ while lifting its price target.&nbsp;TD Cowen raised its price target on Rivian shares to $20 from $17, according to TheFly.&nbsp;<h2 class="st-heading-2">R2 Growth Potential</h2>The revised outlook comes as the firm evaluated potential demand for Rivian’s upcoming R2 vehicle platform, which could significantly expand the company’s market reach.TD Cowen’s analysts estimate that demand for R2 could eventually range from roughly 212,000 to 335,000 vehicles. They noted that this projection may exceed current Wall Street expectations for 2027.&nbsp;Following the upgrade,&nbsp;<a href="https://stocktwits.com/symbol/RIVN">Rivian Automotive stock</a> traded over 4% higher in Tuesday’s premarket.&nbsp;On Stocktwits, retail sentiment around the stock jumped to ‘bullish’ from ‘neutral’ territory the previous day amid ‘low’ message volume levels.&nbsp;<h2 class="st-heading-2">The Affordable R2 Lineup&nbsp;</h2>The next-generation EVs are expected to target a broader, more affordable segment of the EV market than Rivian’s current R1 lineup. By expanding into a larger customer base, Rivian aims to ramp up production and improve long-term revenue growth.Rivian plans to price the R2 SUV at roughly $45,000, cheaper than the R1 models that start around $70,000. The R2 roll-out will begin in the second-quarter (Q2).&nbsp;In its fourth-quarter (Q4) earnings call, Rivian CFO Claire McDonough noted that the operational complexity tied to the R2 rollout could put pressure on automotive gross profit in Q2 and the third quarter of 2026, even though total gross profit is expected to rise compared with the previous year.RIVN stock has gained over 57% in the last 12 months.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/nvidia-ceo-jensen-huang-frames-ai-as-foundational-infrastructure-ahead-of-gtc-event-next-week/cZdotbFRI7J">Nvidia CEO Jensen Huang Frames AI As ‘Foundational Infrastructure’ Ahead Of GTC Event Next Week</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

The Rivian logo is on display during the 2025 Los Angeles Auto Show at the Los Angeles Convention Center on November 23, 2025 in Los Angeles, California

RIVN Stock Gains 4% Pre-Market After TD Cowen Upgrade: Analyst Sees Strong Demand For Upcoming R2 Models

Rivian Automotive Inc. (RIVN) received a vote of confidence from TD Cowen, which upgraded the electric vehicle maker’s stock to a ‘Buy’ rating from ‘Hold’ while lifting its price target. 

The firm believes the new lineup could significantly expand Rivian's addressable EV market.

CRISPR Therapeutics Pivots Beyond Casgevy, Highlights CTX310 Data and New Cardiovascular Push

CRISPR Therapeutics (NASDAQ:CRSP) used a fireside chat at TD Cowen's 46th Annual Healthcare Conference to outline how the company is trying to broaden its identity beyond its first commercial...

SR One Capital Management LP Has $132.13 Million Stock Position in CRISPR Therapeutics AG $CRSP

SR One Capital Management LP increased its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 94.4% during the 3rd quarter, according to its most recent filing with the...

Citigroup Inc. Sells 88,203 Shares of CRISPR Therapeutics AG $CRSP

Citigroup Inc. decreased its position in CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 59.3% in the third quarter, according to the company in its most recent disclosure with the Securities...

CRISPR Therapeutics AG $CRSP is ARK Investment Management LLC's 8th Largest Position

ARK Investment Management LLC decreased its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 3.9% during the third quarter, according to the company in its most recent...

Forget CRISPR Therapeutics: This Gene Editing Player Already Boasts the Profits It Dreams Of

Key PointsCRISPR Therapeutics' gene-editing platform looks fairly promising, but plenty of challenges could sink the stock...

Is CRISPR Therapeutics Stock Too Risky to Buy Right Now?

Key PointsCRISPR obtained approval for Casgevy back in 2023, but the rollout has been slow...

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

CRISPR Therapeutics AG

Beat EPS and revenue

Beat EPS, miss revenue

Miss EPS, beat revenue

Miss EPS and revenue

What do you expect from $ORCL earnings Tuesday?

Stocktwits

Stocktwits Polls

The announced $350M convertible senior notes offering has triggered significant debate and concern over potential dilution and the company's financial strategy.

Widespread frustration is mounting over leadership's decision to raise capital despite a substantial cash reserve, prompting questions about their strategic vision.

Despite the recent capital raise, users continue to speculate about a potential acquisition, often mentioning an existing partner as a likely suitor.

Opportunistic traders are actively identifying and setting buy limits at discounted prices, anticipating a rebound from the recent drop.

Current Price	$52.80
Prev Close	$58.78
Open	$53.94
Dividend Yield	0.00%
50-Day Moving Average	$54.47
Beta	1.53
Avg. Volume	1.69M
PE Ratio	-9.02

52-Week High	$78.48
52-Week Low	$30.04
Market Capitalization	$5.65B
EPS (Annual)	-$6.47
Price to Book	2.93
Revenue Per Employee	$8,931.30

CRSP
CRISPR Therapeutics AG

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRSP News

CRSPCRISPR Therapeutics AG